1 Executive Summary
1.1 Aims of the Report
1.2 Scope of the Report
2 Introduction to Reproductive Therapeutics
2.1 Mechanism of Action of Contraceptives
2.2 Combination Pills
2.2.1 Phasic Combination Pills
2.2.1.1 Monophasic Combination Pills
2.2.1.2 Biphasic Combination Pills
2.2.1.3 Triphasic Combination Pills
2.2.2 Regular Dose Combination Pills
2.2.3 Twenty Four-Day Packs
2.2.4 Extended Cycle Pills
2.2.5 Low Dose Combination Pills
2.2.6 High Dose Combination Pills
2.3 Progestin-Only Pills
2.4 Polycystic Ovarian Syndrome Medications
2.5 Oral Pills for Premenstrual Syndrome (PMS)
2.6 Hormonal Treatments for Endometriosis
2.7 Unwanted Pregnancy/Emergency Contraception
2.7.1 Plan B
2.7.2 Preven Faces Withdrawal from the Market in Favour of Plan B
2.8 Menopause and Improvement of Quality of Life with Hormone Replacement Therapy (HRT)
2.8.1 Wyeth's Premarin and Prempro for HRT
2.8.2 HRT for Prevention and Treatment of Osteoporosis
2.8.3 Natural Hormone Option for Breast Cancer Risk in Place of HRT
2.9 Folic Acid for Pregnant Women
2.10 Antiretroviral (ARV) Drugs Taken By HIV Positive Pregnant Women
2.10.1 Taking Zidovudine for the Prevention of Mother-To-Child Transmission of HIV
2.11 Artificial Insemination for HIV Positive Parent
2.12 Pregnancies Induced by Clomifene
2.13 Recombinant Gonadotropin for Female Infertility
2.14 Pelvic Inflammatory Disease Causes Infertility
2.15 Proprietary and Generic Contraceptive Pills
2.15.1 Warner Chilcott Received Patent Challenge on Oral Contraceptive
2.15.2 Bayer Schering Sues Watson Over Generic Yaz Application
2.15.3 Warner Chilcott Sues Watson Over Generic Femcon FE Application
2.15.4 Barr Attempts to Prevent Watson Marketing Seasonique
2.15.5 Patent Information for Hormonal Contraceptive Pills
2.16 Generic Clomifene Citrate as Fertility Medications
2.17 Natural Oestrogen To Treat Oestrogen-Dependent Disorders
2.18 Less Expensive Version of Premarin Not Available
3 Women’s Reproductive Disorders Therapeutics Market
3.1 World Hormonal Contraceptive Market
3.2 Major World Markets for Hormonal Contraceptives
3.2.1 Contraceptive Market Forecast for the US
3.2.2 Market Penetration for FDA-Approved Hormonal Contraceptives in Europe
3.2.3 Forecast for Hormonal Contraceptives in the UK
3.2.4 Forecast for Hormonal Contraceptives in Germany
3.2.5 Forecast for Hormonal Contraceptives in France
3.2.6 Marked Variation in Sales Forecasts between Italy's and Spain's Markets
3.2.7 Forecast for Contraceptive Use in Australia Shows Significant Growth Rate
3.2.8 Forecast for Contraceptive Use in Russia Shows High Growth Rate
3.2.9 Market Forecast for Highly Populated China
3.2.10 Contraceptive Market Forecast for Canada
3.2.11 Hormonal Contraceptive a Growing Market for Japan
3.3 Bayer Schering Dominates Global Market for Oral Contraceptives
3.4 Global Market for Hormonal Oral Contraceptives
3.4.1 Bayer Schering the Market Leader for Hormonal Oral Contraceptives
3.4.1.1 Yasmin was the Leading Product in the Market
3.4.1.2 Yaz and Loestrin 24 Fe Among Leading Products in the Market for Oral Contraceptives
3.4.1.3 Microgynon among the Highest Selling Oral Contraceptives
3.4.1.4 Meliane Marketed Internationally with High Sales Rating
3.4.2 Schering-Plough has a Significant Share in Hormonal Oral Contraceptive Market
3.4.2.1 Mercilon and Marvelon Listed Among Highest Selling Products without a US Market Penetration
3.4.2.2 Cerazette is an Oestrogen-Free Contraceptive with High Predicted Growth
3.4.3 Barr's Generic Product Tri-Sprintec has a Significant Market Share
3.5 Bayer Schering's Market for Hormonal Oral Contraceptives in the US
3.6 Both Proprietary and Generic Oral Hormonal Contraceptives Show Strong Growth
3.7 Other Hormonal Methods Pose Increased Competition for Hormonal Oral Contraceptives
3.7.1 NuvaRing's Growth Shows High CAGR
3.7.2 Setback in the Market for Contraceptive Patches
3.8 Depo-Provera to be Used for More than Two Years
3.9 Hormone Replacement Therapy Market Recovers
3.10 Types of Hormone Replacement Therapy
3.11 Market for Fertility Medications
3.12 Market for Folic Acid
4 SWOT Analysis for Hormonal Oral Contraceptive Market
4.1 SWOT Analysis for Hormonal Oral Contraceptive Market
4.2 Risk Analysis for Extended-Cycle Oral Contraceptive Market
4.3 Interview with Dr Heather Currie, NHS
4.3.1 Delivery System for Hormonal Oral Contraceptive
4.3.2 Transdermal Patch can be an Option for Some
4.3.3 Long-Acting Reversible Contraceptive as an Option
4.3.4 Extended Cycle Pills Provide Hope for Both Conception and Premenstrual Syndrome
4.3.5 New Hormonal Oral Contraceptive for European Market
5 SWOT Analysis for Hormone Replacement Therapy (HRT) Market
5.1 SWOT Analysis for Hormone Replacement Therapy (HRT) Market
5.2 Interview with Dr Heather Currie, Menopause Matters
5.2.1 Professionals to Make Informed Choices About HRT
5.2.2 Negative Publicity for HRT in the Recent Past
5.2.3 Signs of Hope Seen for HRT Market since Earlier Negative Publicity
5.2.4 Market for HRT Faced Difficulty After Study Results
5.2.5 Patients are Puzzled over Trial Results
5.2.6 HRT Market is Recovering since it Experienced a Slump
5.2.7 Patients are Opting for HRT after a Pause
5.2.8 Growth Will be Low from 2008 to 2018
5.2.9 Trial Has Begun for Younger Menopausal Age Group
5.2.10 Treatment Options for Menopause are Individualised
6 PEST Analysis for Undertaking Infertility Treatment
6.1 Social Analysis: Infertility Has an Impact on Society
6.2 Technological Analysis: Infertility Treatment Provides Hope for Many Couples
6.3 Technological Analysis: Usefulness of IVF or Intracytoplasmic Sperm Injection (ICSI)
6.4 Socio-Economic Analysis: Prevalence Rates for Infertility
6.5 Economic Analysis: Artificial Insemination Cheaper than IVF
6.6 Economic Analysis: Patients Seek Costly Private Sector IVF Treatment
6.7 Regulatory Affairs / Political Analysis: Guidelines for National Healthcare Service to be Reviewed
6.8 Interview with Dr Heather Currie, NHS Scotland
6.8.1 Clinical Trial with Fertility Medications
6.8.2 Lifestyle Management alongside Fertility Medications
6.8.3 NICE Recommendation for Age Limit for Fertility Treatment
6.8.4 Chlamydia Antibiotic Drug Becomes OTC
7 Research and Development (R&D) for Women’s Reproductive Disorders
7.1 R&D Products for Hormonal Contraception
7.2 Interview with Dr Heather Currie, NHS
7.2.1 Oral Contraceptive Pills Having Additional Therapeutic Effects
7.3 Bayer Schering Leading in R&D Products for Hormonal Contraception
7.3.1 Bayer Schering is Considering a Pill Containing Oestradiol in Place of Synthetic Ethinyl Oestradiol
7.3.2 Drospirenone in Yasmin and Yaz Have Additional Therapeutic Effects
7.3.3 Further Product Line Extension for Pills Containing Drospirenone
7.3.4 Bayer Schering's Improved Contraceptive Patch
7.3.5 Bayer Schering's Work on Male Pill
7.4 Studies Underway to Compare Individual Oral Hormonal Contraceptive with Yasmin
7.5 HRT Pipeline Information
7.5.1 Angeliq was a Follow-On Version of Yasmin for HRT Indication
7.6 Acquisition of Organon by Schering-Plough
7.7 Lifecycle Management of Organon's Fertility Medications
8 Conclusions
8.1 The Future Market for Hormonal Contraceptives
8.2 Mergers and Acquisitions
8.3 Lifecycle Management and Product Line Extension
8.4 The Menopause Market and Hormone Replacement Therapy
8.5 Future of Popular Fertility Medications
List of Tables
Table 2.1 List of HRT Medications According to Type of Hormone Used
Table 2.2 Patent Information for Hormonal Contraceptive Pills
Table 3.1 World Hormonal Contraceptives Market Forecast, 2008-2018
Table 3.2 US Hormonal Contraceptives Market Forecast, 2008-2018
Table 3.3 UK's Hormonal Contraceptives Market Forecast, 2008-2018
Table 3.4 Germany's Hormonal Contraceptives Market Forecast, 2008-2018
Table 3.5 France's Hormonal Contraceptives Market Forecast, 2008-2018
Table 3.6 Italy's Hormonal Contraceptives Market Forecast, 2008-2018
Table 3.7 Spain's Hormonal Contraceptives Market Forecast, 2008-2018
Table 3.8 Australia's Hormonal Contraceptives Market Forecast, 2008-2018
Table 3.9 Russian Fed.'s Hormonal Contraceptives Market Forecast, 2008-2018
Table 3.10 China's Hormonal Contraceptives Market Forecast, 2008-2018
Table 3.11 Canada's Hormonal Contraceptives Market Forecast, 2008-2018
Table 3.12 Highest Selling Hormonal Oral Contraceptives, 2007/2008
Table 3.13 Yasmin Market Forecast, 2008-2018
Table 3.14 Yaz Market Forecast, 2008-2018
Table 3.15 Loestrin 24 Fe Market Forecast, 2008-2018
Table 3.16 Microgynon 30 Market Forecast, 2008-2018
Table 3.17 Mercilon Market Forecast, 2008-2018
Table 3.18 Marvelon Market Forecast, 2008-2018
Table 3.19 Cerazette Market Forecast, 2008-2018
Table 3.20 Highest Selling Systemic Hormonal Non-Oral Contraceptive Market, 2007/2008
Table 3.21 HRT Market Forecast, 2008-2018
Table 3.22 Highest-Selling Oestrogen Replacement Therapies, 2007/2008
Table 3.23 Highest-Selling Progestin-Only Therapies, 2007/2008
Table 3.24 Highest-Selling Combined HRT Therapies, 2007/2008
Table 3.25 Highest-Selling Androgen Therapies, 2007/2008
Table 3.26 High Selling Fertility Medications Market, 2007/2008
Table 3.27 Market for Folic Acid, 2007/2008
Table 4.1 SWOT Analysis for Hormonal Oral Contraceptive Market
Table 4.2, Risk Analysis for Extended-Cycle Oral Contraceptive Market
Table 5.1 SWOT Analysis for HRT Market
Table 7.1 Pipeline Products for Women's Reproductive Disorders
List of Figures
Figure 3.1 World Hormonal Contraceptives Market Forecast, 2008-2018
Figure 3.2 Major Market Revenue for Hormonal Contraceptives, 2007
Figure 3.3 Major Market Growth Rate for Hormonal Contraceptives in 2007
Figure 3.4 US Hormonal Contraceptives Market Forecast, 2008-2018
Figure 3.5 UK's Hormonal Contraceptives Market Forecast, 2008-2018
Figure 3.6 Germany's Hormonal Contraceptives Market Forecast, 2008-2018
Figure 3.7 France's Hormonal Contraceptives Market Forecast, 2008-2018
Figure 3.8 Italy's Hormonal Contraceptives Market Forecast, 2008-2018
Figure 3.9 Spain's Hormonal Contraceptives Market Forecast, 2008-2018
Figure 3.10 Australia's Hormonal Contraceptives Market Forecast, 2008-2018
Figure 3.11 Russian Fed.'s Hormonal Contraceptives Market Forecast, 2008-2018
Figure 3.12 China's Hormonal Contraceptives Market Forecast, 2008-2018
Figure 3.13 Canada's Hormonal Contraceptives Market Forecast, 2008-2018
Figure 3.14 Yasmin Market Forecast, 2008-2018
Figure 3.15 Yaz Market Forecast, 2008-2018
Figure 3.16 Loestrin 24 Fe Market Forecast, 2008-2018
Figure 3.17 Microgynon 30 Market Forecast, 2008-2018
Figure 3.18 Mercilon Market Forecast, 2008-2018
Figure 3.19 Marvelon Market Forecast, 2008-2018
Figure 3.20 Cerazette Market Forecast, 2008-2018
Figure 3.21 HRT Market Forecast, 2008-2018